279 related articles for article (PubMed ID: 20041879)
1. L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats.
O'Brien D; Chunduri P; Iyer A; Brown L
Basic Clin Pharmacol Toxicol; 2010 Apr; 106(4):296-301. PubMed ID: 20041879
[TBL] [Abstract][Full Text] [Related]
2. Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats.
Chan V; Hoey A; Brown L
Br J Pharmacol; 2006 Aug; 148(7):902-8. PubMed ID: 16783413
[TBL] [Abstract][Full Text] [Related]
3. Reversal of cardiac dysfunction by selective ET-A receptor antagonism.
Allan A; Fenning A; Levick S; Hoey A; Brown L
Br J Pharmacol; 2005 Nov; 146(6):846-53. PubMed ID: 16151437
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats.
Iyer A; Woodruff TM; Wu MC; Stylianou C; Reid RC; Fairlie DP; Taylor SM; Brown L
J Cardiovasc Pharmacol; 2011 Nov; 58(5):479-86. PubMed ID: 21753735
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats.
Loch D; Levick S; Hoey A; Brown L
J Cardiovasc Pharmacol; 2006 Mar; 47(3):396-404. PubMed ID: 16633082
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
Loch D; Hoey A; Brown L
Clin Exp Hypertens; 2006 Jul; 28(5):475-88. PubMed ID: 16820344
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats.
Chan V; Fenning A; Iyer A; Hoey A; Brown L
Curr Pharm Biotechnol; 2011 Mar; 12(3):429-36. PubMed ID: 20874677
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats.
Mirkovic S; Seymour AM; Fenning A; Strachan A; Margolin SB; Taylor SM; Brown L
Br J Pharmacol; 2002 Feb; 135(4):961-8. PubMed ID: 11861324
[TBL] [Abstract][Full Text] [Related]
9. Morin attenuates blood pressure and oxidative stress in deoxycorticosterone acetate-salt hypertensive rats: a biochemical and histopathological evaluation.
Prahalathan P; Kumar S; Raja B
Metabolism; 2012 Aug; 61(8):1087-99. PubMed ID: 22386933
[TBL] [Abstract][Full Text] [Related]
10. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.
Ogata T; Miyauchi T; Sakai S; Takanashi M; Irukayama-Tomobe Y; Yamaguchi I
J Am Coll Cardiol; 2004 Apr; 43(8):1481-8. PubMed ID: 15093887
[TBL] [Abstract][Full Text] [Related]
11. Cardiac and vascular responses in deoxycorticosterone acetate-salt hypertensive rats.
Brown L; Ooi SY; Lau K; Sernia C
Clin Exp Pharmacol Physiol; 2000 Apr; 27(4):263-9. PubMed ID: 10779123
[TBL] [Abstract][Full Text] [Related]
12. Effect of manidipine on cardiac hypertrophy and coronary circulation in DOCA/salt hypertensive rats.
Takeda K; Nakata T; Kuwabara T; Itoh H; Yamahara Y; Takesako T; Tanabe S; Sasaki S; Asayama J; Nakagawa M
Blood Press Suppl; 1992; 3():48-52. PubMed ID: 1343289
[TBL] [Abstract][Full Text] [Related]
13. Increased reactive oxygen species contributes to kidney injury in mineralocorticoid hypertensive rats.
Jin L; Beswick RA; Yamamoto T; Palmer T; Taylor TA; Pollock JS; Pollock DM; Brands MW; Webb RC
J Physiol Pharmacol; 2006 Sep; 57(3):343-57. PubMed ID: 17033089
[TBL] [Abstract][Full Text] [Related]
14. Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms.
Callera GE; Tostes RC; Yogi A; Montezano AC; Touyz RM
Clin Sci (Lond); 2006 Feb; 110(2):243-53. PubMed ID: 16271043
[TBL] [Abstract][Full Text] [Related]
15. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
Brown L; Duce B; Miric G; Sernia C
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155
[TBL] [Abstract][Full Text] [Related]
16. l-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats.
Fenning A; Harrison G; Rose'meyer R; Hoey A; Brown L
Am J Physiol Heart Circ Physiol; 2005 Oct; 289(4):H1408-16. PubMed ID: 15923320
[TBL] [Abstract][Full Text] [Related]
17. Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension.
Gómez-Guzmán M; Jiménez R; Sánchez M; Zarzuelo MJ; Galindo P; Quintela AM; López-Sepúlveda R; Romero M; Tamargo J; Vargas F; Pérez-Vizcaíno F; Duarte J
Free Radic Biol Med; 2012 Jan; 52(1):70-9. PubMed ID: 22001745
[TBL] [Abstract][Full Text] [Related]
18. A possible correlation between the correction of endothelial dysfunction and normalization of high blood pressure levels by 1,3,4-oxadiazole derivative, an L-type Ca2+ channel blocker in deoxycorticosterone acetate and N(G)-nitro-l-arginine hypertensive rats.
Bankar GR; Nampurath GK; Nayak PG; Bhattacharya S
Chem Biol Interact; 2010 Jan; 183(2):327-31. PubMed ID: 19912999
[TBL] [Abstract][Full Text] [Related]
19. Polyphenols restore endothelial function in DOCA-salt hypertension: role of endothelin-1 and NADPH oxidase.
Jiménez R; López-Sepúlveda R; Kadmiri M; Romero M; Vera R; Sánchez M; Vargas F; O'Valle F; Zarzuelo A; Dueñas M; Santos-Buelga C; Duarte J
Free Radic Biol Med; 2007 Aug; 43(3):462-73. PubMed ID: 17602962
[TBL] [Abstract][Full Text] [Related]
20. 5-Hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats.
Diaz J; Ni W; Thompson J; King A; Fink GD; Watts SW
J Pharmacol Exp Ther; 2008 Jun; 325(3):1031-8. PubMed ID: 18305011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
